J&J Antibacterial Drug Risky For Pneumonia Patients: FDA
The FDA warned Thursday that Johnson & Johnson antibacterial drug Doribax poses a higher risk of death when used in patients who develop pneumonia while on ventilators compared to other antibacterial...To view the full article, register now.
Already a subscriber? Click here to view full article